ZA200908943B - Pyrazolopyrimidinone kinase inhibitor - Google Patents

Pyrazolopyrimidinone kinase inhibitor

Info

Publication number
ZA200908943B
ZA200908943B ZA200908943A ZA200908943A ZA200908943B ZA 200908943 B ZA200908943 B ZA 200908943B ZA 200908943 A ZA200908943 A ZA 200908943A ZA 200908943 A ZA200908943 A ZA 200908943A ZA 200908943 B ZA200908943 B ZA 200908943B
Authority
ZA
South Africa
Prior art keywords
pyrazolopyrimidinone
kinase inhibitor
kinase
inhibitor
pyrazolopyrimidinone kinase
Prior art date
Application number
ZA200908943A
Other languages
English (en)
Inventor
Arthur F Kluge
Original Assignee
Agennix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Ag filed Critical Agennix Ag
Publication of ZA200908943B publication Critical patent/ZA200908943B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200908943A 2007-05-29 2009-12-15 Pyrazolopyrimidinone kinase inhibitor ZA200908943B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93215507P 2007-05-29 2007-05-29
EP07113226A EP2019101A1 (fr) 2007-07-26 2007-07-26 Pyrazol[3,4-d]pyrimidin-4-one utile en tant que Inhibiteur de kinase

Publications (1)

Publication Number Publication Date
ZA200908943B true ZA200908943B (en) 2010-08-25

Family

ID=38556321

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200908943A ZA200908943B (en) 2007-05-29 2009-12-15 Pyrazolopyrimidinone kinase inhibitor

Country Status (19)

Country Link
US (2) US8304418B2 (fr)
EP (2) EP2019101A1 (fr)
JP (1) JP2010528088A (fr)
KR (1) KR20100040806A (fr)
CN (1) CN101765600A (fr)
AR (1) AR066737A1 (fr)
AT (1) ATE522533T1 (fr)
AU (1) AU2008257534A1 (fr)
CA (1) CA2689090A1 (fr)
DK (1) DK2170891T3 (fr)
EA (1) EA200901536A1 (fr)
ES (1) ES2370677T3 (fr)
HR (1) HRP20110768T1 (fr)
IL (1) IL202375A0 (fr)
MX (1) MX2009012832A (fr)
SI (1) SI2170891T1 (fr)
TW (1) TW200906831A (fr)
WO (1) WO2008145678A1 (fr)
ZA (1) ZA200908943B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660146T3 (es) * 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
WO2013059634A1 (fr) 2011-10-20 2013-04-25 The Regents Of The University Of California Utilisation d'inhibiteurs de cdk9 pour réduire la dégradation cartilagineuse
WO2015172713A1 (fr) * 2014-05-13 2015-11-19 广东东阳光药业有限公司 Méthode de préparation d'un intermédiaire
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
WO2026024674A1 (fr) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Méthodes de traitement de cancers associés à skp2

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
EG18377A (en) 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6559152B2 (en) * 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
EP1156060B1 (fr) 2000-05-12 2007-06-27 GPC Biotech AG Peptides/protéines humaines causant ou menant à la mort de cellules y compris de cellules lymphoides tumorales
IT1317975B1 (it) 2000-06-16 2003-07-21 Christian Pio Pedulla Presa multipla volante.
WO2003063764A2 (fr) * 2001-07-10 2003-08-07 Bristol-Myers Squibb Pharma Company Derives de pyrazolo[3,4-d]pyrimidin-4-ones substitues en position 6 utiles en tant qu'inhibiteurs de la kinase dependante des cyclines
CA2463571A1 (fr) * 2001-10-15 2003-04-24 Gpc Biotech, Inc. Inhibiteurs de kinases dependantes des cyclines, compositions et utilisations associees
US7786112B2 (en) * 2003-04-07 2010-08-31 Agennix Usa Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
EP1678147B1 (fr) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
EA013117B1 (ru) 2003-12-23 2010-02-26 ДжиПиСи БАЙОТЕК, ИНК. Ингибиторы циклинзависимых киназ, относящиеся к ним композиции и применения

Also Published As

Publication number Publication date
WO2008145678A1 (fr) 2008-12-04
SI2170891T1 (sl) 2011-12-30
EP2019101A1 (fr) 2009-01-28
KR20100040806A (ko) 2010-04-21
IL202375A0 (en) 2010-06-30
US20130035349A1 (en) 2013-02-07
CN101765600A (zh) 2010-06-30
DK2170891T3 (da) 2011-12-12
EA200901536A1 (ru) 2010-06-30
MX2009012832A (es) 2010-05-17
ATE522533T1 (de) 2011-09-15
EP2170891B1 (fr) 2011-08-31
EP2170891A1 (fr) 2010-04-07
US20100160350A1 (en) 2010-06-24
AU2008257534A1 (en) 2008-12-04
US8304418B2 (en) 2012-11-06
CA2689090A1 (fr) 2008-12-04
AR066737A1 (es) 2009-09-09
TW200906831A (en) 2009-02-16
ES2370677T3 (es) 2011-12-21
HRP20110768T1 (hr) 2011-11-30
JP2010528088A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
ZA200901073B (en) Kinase inhibitor
PL2079727T3 (pl) Inhibitory kinazy
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL213464A0 (en) Kinase inhibitor compounds
ZA201002543B (en) Polo-like kinase inhibitors
ZA200900109B (en) Pyrrolotriazine kinase inhibitors
IL201564A0 (en) P70 s6 kinase inhibitors
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL194424A0 (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
EP2166857A4 (fr) Composés d'inhibiteur de kinase
EP2222166A4 (fr) Inhibiteurs de kinases hétérocycliques
EP2036893A4 (fr) INHIBITEUR DE KINASE Abl
IL202375A0 (en) Pyrazolopyrimidinone kinase inhibitor
IL197981A0 (en) Kinase inhibitors
GB0603522D0 (en) Kinase inhibition
GB0608854D0 (en) P13 kinase inhibitors
GB0714941D0 (en) Inhibitors
GB0606238D0 (en) Kinase inhibition
GB0720364D0 (en) Inhibitor
GB0713152D0 (en) Phosphodlesterase inhibitors
HK1143036A (en) Kinase inhibitor compounds
GB0707495D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors
GB0707497D0 (en) Novel inhibitors